HI
CYCN icon

HBK Investments’s Cyclerion Therapeutics CYCN Stock Holding History

HBK Investments’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-999
Closed -$242K – 681
2019
Q3 		$242K Hold
999
– – ﹤0.01% 585
2019
Q2 		$229K Buy
+999
New +$283K ﹤0.01% 560

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HBK Investments's CYCN Position: Q4 2019 in Review

HBK Investments sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 999 shares — an estimated $242K sold.

HBK Investments first reported a position in CYCN in Q2 2019 and held it in 2 quarters. The position peaked at $242K in Q3 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

  • HBK Investments reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • HBK Investments sold 999 Cyclerion Therapeutics shares in Q4 2019, an estimated $242K.
  • HBK Investments first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 2 quarters.
  • HBK Investments's Cyclerion Therapeutics position peaked at $242K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on HBK Investments's 13F filing for Q4 2019, filed 14 Feb 2020.